Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Sutro Biopharma Inc’s stock clocked out at $0.95, down -9.51% from its previous closing price of $1.05. In other words, the price has decreased by -$9.51 from its previous closing price. On the day, 1.83 million shares were traded.
Ratios:
To gain a deeper understanding of STRO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.60 and its Current Ratio is at 2.60. In the meantime, Its Debt-to-Equity ratio is 4.57 whereas as Long-Term Debt/Eq ratio is at 4.41.
On March 14, 2025, Wedbush Downgraded its rating to Neutral which previously was Outperform and also lowered its target price recommendation from $8 to $2.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.29 while its Price-to-Book (P/B) ratio in mrq is 1.76.
Stock Price History:
Over the past 52 weeks, STRO has reached a high of $5.17, while it has fallen to a 52-week low of $0.52. The 50-Day Moving Average of the stock is 0.29%, while the 200-Day Moving Average is calculated to be -63.02%.
Shares Statistics:
A total of 82.53M shares are outstanding, with a floating share count of 75.84M. Insiders hold about 10.10% of the company’s shares, while institutions hold 71.22% stake in the company.
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$2.48 and -$2.48 for the fiscal current year, implying an average EPS of -$2.48. EPS for the following year is -$0.44, with 2.0 analysts recommending between -$0.2 and -$0.67.
